Concomitant chemoradiotherapy yields a greater survival benefit in patients with MGMT (O6-methylguanine DNA methyltransferase) promoter methylation, a biomarker with both prognostic and therapeutic implications for glioblastoma management. The gene discussed is MGMT; the disease is glioblastoma.